PAF v AbbVie excessive pricing case the Netherlands

On 14 May 2024, the Pharmaceutical Accountability Foundation (PAF) had their first hearing in their case against Abbvie at the Amsterdam District Court. The case concerns Abbvie’s pricing practices for its blockbuster drug Humira (adalimumab), one of the world’s best-selling… Continue Reading

KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer

Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading

KEI Comments on NIH Exclusive License to INTcRON

On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading